Froedtert Hospital

Running trials

• Recruiting

  Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial

  NCT07227077· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Source

• Active, not recruiting

  Intensive Postpartum Antihypertensive Treatment

  NCT05687344· Phase 3· Source

• Active, not recruiting

  Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

  NCT03967223· Phase 2· Source

• Enrolling by invitation

  Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

  NCT03391778· Phase 1· Source

• Recruiting

  EMST in Patients Undergoing CRT for HNCA

  NCT03916809· Source

• Recruiting

  Intra- and Inter-fraction Changes in Radiation Therapy

  NCT02344121· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  GLP-1 RA on Liver OMICS in MASLD

  NCT06982378· Source

• Withdrawn

  Assessment of Fatty Liver With Thermo-acoustic Device

  NCT04302051· Source

• Terminated

  A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

  NCT05028751· Phase 1/2· Source

• Completed

  Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients

  NCT05255445· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Source

• Completed

  A Study of DF6002 Alone and in Combination With Nivolumab

  NCT04423029· Phase 1· Source

• Recruiting

  Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

  NCT03907046· Phase 3· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

  NCT05993299· Phase 2· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT06703346· Phase 2· Source

• Terminated

  EMST and Swallowing in Long-Term Survivors of HNCA

  NCT03975465· Source

• Completed

  MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

  NCT01972919· Phase 2· Source